Determination of recombinant glycosylated proteins and peptides in biological fluids
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 25, 2006
Grant Date -
Mar 18, 2004
app pub date -
Jun 3, 2003
filing date -
Apr 21, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Polyclonal antibodies can be produced that reacts with recombinant EPO and its degradation products but not with native EPO. This antibody precipitation can be used to identify those glycopeptides that are uniquely reactive. These glycopeptides can be produced on preparative scale and used in the production of monoclonal antibodies which are screened against the original EPO and glycopeptides to select antibodies reactive to the specific glycopeptides an recombinant EPO but not to native human EPO. The monoclonal antibodies so selected are incorporated in a conventional ELISA and used to monitor urine and other bodily samples taken from athletes, either human or animal, and patients for presence and level of recombinant peptides or proteins. Alternatively, the polyclonal antibody can be used directly to produce ELISA tests.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully